Brief: Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
20/11/2024 13:57
Nov 20 (Reuters) - RenovoRx Inc RNXT.O :
* NORTHWELL HEALTH CANCER INSTITUTE LAUNCHES PATIENT
ENROLLMENT IN
RENOVORX’S ONGOING PIVOTAL PHASE III TIGER-PAC CLINICAL TRIAL
Source text: ID:nGNX423LKb
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies